NEW YORK, Sept. 4 - Shanghai IgCon Therapeutics, a joint venture of Genetastix and the South Gene Technology Company, got the official green light to begin operations from the Shanghai municipal government, the companies said today.
Shanghai IgCon Therapeutics, established last November, will focus on pre-clinical and clinical development of human therapeutic antibodies for the Chinese and Asian markets, according to the company.
The South Gene Technology Company is the commercial arm of the National Human Genome Center of Shanghai, which was established in 1998.
Genetastix is based in
For further information, see the press release.